The role of protein kinase C-alpha in hematologic malignancies

被引：18

作者：

Lahn, M ^{[1
]}

Sundell, K

Köhler, G

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Div Oncol Prod Dev, Indianapolis, IN 46285 USA

[2] Univ Munster, Inst Pathol, D-4400 Munster, Germany

来源：

ACTA HAEMATOLOGICA | 2006年 / 115卷 / 1-2期

关键词：

acute myelogenous leukemia; antisense oligonucleotide; aprinocarsen; non-Hodgkin lymphoma; PKC-alpha; targeted agents;

D O I：

10.1159/000089458

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In recent years advances in histopathological and molecular understanding of hematologic malignancies have led to the development of drugs which selectively target proteins associated with hematologic tumorigenesis. One such targeted agent is the antisense oligonucleotide aprinocarsen, which specifically inhibits the signaling protein, protein kinase C-alpha (PKC-alpha). Although PKC-alpha has been associated with tumorigenesis, its role and expression levels in patients with hematologic malignancies are not well understood. We here review studies investigating the expression and role of PKC-alpha in hematologic malignancies. Such a review may offer new insights on how to develop strategies in identifying patients that might best benefit from PKC-alpha inhibition. Copyright (C) 2006 S. Karger AG, Basel.

引用

页码：1 / 8

页数：8

共 67 条

[1]

AHMAD S, 1992, MOL PHARMACOL, V42, P1004

[2] The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes [J].

Alizadeh, A ;

Eisen, M ;

Davis, RE ;

Ma, C ;

Sabet, H ;

Tran, T ;

Powell, JI ;

Yang, L ;

Marti, GE ;

Moore, DT ;

Hudson, JR ;

Chan, WC ;

Greiner, T ;

Weisenburger, D ;

Armitage, JO ;

Lossos, I ;

Levy, R ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1999, 64 :71-78

[3]

*AM CANC SOC, 2004, SOC AC CANC FACTS FI

[4] Protein kinase C isoforms in normal and chronic myeloid leukemic neutrophils.: Distinct signal for PKC α by immunodetection on PVDF membrane, decreased expression of PKC α and increased expression of PKC δ in leukemic neutrophils [J].

Balasubramanian, N ;

Advani, SH ;

Zingde, SM .

LEUKEMIA RESEARCH, 1998, 22 (07) :597-604

[5] THE POTENTIAL OF PROTEIN-KINASE-C AS A TARGET FOR ANTICANCER TREATMENT [J].

BASU, A .

PHARMACOLOGY & THERAPEUTICS, 1993, 59 (03) :257-280

[6] Vitamin D analogs, 20-epi-22-oxa-24a,26a,27a,-trihomo-1α,25(OH)2-vitamin D3, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3 and 1α,25(OH)2-lumisterol3 prime NB4 leukemia cells for monocytic differentiation via nongenomic signaling pathways, involving calcium and calpain [J].

Berry, DM ;

Meckling-Gill, KA .

ENDOCRINOLOGY, 1999, 140 (10) :4779-4788

[7]

Bianchi A, 1997, BRIT J HAEMATOL, V97, P815

[8] REGULATION OF PROTEIN-KINASE-C AND ROLE IN CANCER BIOLOGY [J].

BLOBE, GC ;

OBEID, LM ;

HANNUN, YA .

CANCER AND METASTASIS REVIEWS, 1994, 13 (3-4) :411-431

[9] Differential inhibition by α- and β-tocopherol of human erythroleukemia cell adhesion:: Role of integrins [J].

Breyer, I ;

Azzi, A .

FREE RADICAL BIOLOGY AND MEDICINE, 2001, 30 (12) :1381-1389

[10] Protein kinase c isoenzyme patterns characteristically modulated in early prostate cancer [J].

Cornford, P ;

Evans, J ;

Dodson, A ;

Parsons, K ;

Woolfenden, A ;

Neoptolemos, J ;

Foster, CS .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :137-144

← 1 2 3 4 5 6 7 →